Literature DB >> 2795103

Motor neuropathy with activity of monoclonal IgM antibody to GD1a ganglioside.

E Bollensen1, H I Schipper, A J Steck.   

Abstract

A patient with motor neuropathy associated with monoclonal IgM protein is reported. Using enzyme-linked immunosorbent assays, the antibody activity of the monoclonal IgM was shown to be directed against GD1a ganglioside, a new and so far unreported specificity.

Entities:  

Mesh：

Substances：

Year:  1989        PMID： 2795103     DOI： 10.1007/bf00314380

Source DB:  PubMed          Journal:  J Neurol        ISSN： 0340-5354            Impact factor:   4.849


  12 in total

Review 1.  Peripheral neuropathy associated with monoclonal IgM autoantibody.

Authors:  A J Steck; N Murray; K Dellagi; J C Brouet; M Seligmann
Journal:  Ann Neurol       Date:  1987-12       Impact factor: 10.422

2.  Patterns of serum IgM antibodies to GM1 and GD1a gangliosides in amyotrophic lateral sclerosis.

Authors:  A Pestronk; R N Adams; D Cornblath; R W Kuncl; D B Drachman; L Clawson
Journal:  Ann Neurol       Date:  1989-01       Impact factor: 10.422

3.  Structure of sulfated glucuronyl glycolipids in the nervous system reacting with HNK-1 antibody and some IgM paraproteins in neuropathy.

Authors:  D K Chou; A A Ilyas; J E Evans; C Costello; R H Quarles; F B Jungalwala
Journal:  J Biol Chem       Date:  1986-09-05       Impact factor: 5.157

4.  A treatable multifocal motor neuropathy with antibodies to GM1 ganglioside.

Authors:  A Pestronk; D R Cornblath; A A Ilyas; H Baba; R H Quarles; J W Griffin; K Alderson; R N Adams
Journal:  Ann Neurol       Date:  1988-07       Impact factor: 10.422

5.  Monoclonal IgM in a patient with paraproteinemic polyneuropathy binds to gangliosides containing disialosyl groups.

Authors:  A A Ilyas; R H Quarles; M C Dalakas; P H Fishman; R O Brady
Journal:  Ann Neurol       Date:  1985-12       Impact factor: 10.422

6.  Myelin-associated glycoprotein is the antigen for a monoclonal IgM in polyneuropathy.

Authors:  P E Braun; D E Frail; N Latov
Journal:  J Neurochem       Date:  1982-11       Impact factor: 5.372

7.  Demyelinating neuropathy and monoclonal IgM antibody to myelin-associated glycoprotein.

Authors:  A J Steck; N Murray; C Meier; N Page; G Perruisseau
Journal:  Neurology       Date:  1983-01       Impact factor: 9.910

8.  Reactivity with the peripheral myelin glycoprotein P0 in serum from patients with monoclonal IgM gammopathy and polyneuropathy.

Authors:  E Bollensen; A J Steck; M Schachner
Journal:  Neurology       Date:  1988-08       Impact factor: 9.910

9.  Gangliosides GM1 and GD1b are antigens for IgM M-protein in a patient with motor neuron disease.

Authors:  L Freddo; R K Yu; N Latov; P D Donofrio; A P Hays; H S Greenberg; J W Albers; A G Allessi; D Keren
Journal:  Neurology       Date:  1986-04       Impact factor: 9.910

10.  Motor neuron syndrome and monoclonal IgM with antibody activity against gangliosides GM1 and GD1b.

Authors:  E Nardelli; A J Steck; T Barkas; M Schluep; F Jerusalem
Journal:  Ann Neurol       Date:  1988-05       Impact factor: 10.422
View more
  4 in total

Review 1.  Monoclonal IgM autoantibody reactivity in M-IgM peripheral neuropathy.

Authors:  C Caudie
Journal:  Clin Rev Allergy Immunol       Date:  2000-08       Impact factor: 8.667

2.  Two species of antiganglioside antibodies in a patient with a pharyngeal-cervical-brachial variant of Guillain-Barré syndrome.

Authors:  K Mizoguchi; A Hase; T Obi; H Matsuoka; M Takatsu; Y Nishimura; F Irie; Y Seyama; Y Hirabayashi
Journal:  J Neurol Neurosurg Psychiatry       Date:  1994-09       Impact factor: 10.154

Review 3.  Clinical phenotype of patients with neuropathy associated with monoclonal gammopathy: a comparative study and a review of the literature.

Authors:  Abraham C J Stork; W-Ludo van der Pol; Hessel Franssen; Bart C Jacobs; Nicolette C Notermans
Journal:  J Neurol       Date:  2014-04-30       Impact factor: 4.849

4.  Ganglioside antibodies: a lack of diagnostic specificity and clinical utility?

Authors:  M Weller; A Stevens; N Sommer; J Dichgans; B Kappler; H Wiethölter
Journal:  J Neurol       Date:  1992-10       Impact factor: 4.849
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.